Samsung Epis Holdings shares were rising early on the 15th. Buying appeared to intensify on news that a subsidiary of Samsung Epis Holdings had begun a phase 1 clinical trial for a new drug candidate.
As of 9:20 a.m. that day, Samsung Epis Holdings stock was trading at 579,000 won, up 7.22% (39,000 won) from the previous session.
Samsung Bioepis, a subsidiary of Samsung Epis Holdings, said on the 14th that it had begun a phase 1 clinical trial of the antibody-drug conjugate (ADC) new drug candidate "SBE303." This is the first new drug developed by Samsung Bioepis.
According to ClinicalTrials, the U.S. National Institutes of Health (NIH) clinical trial information disclosure site, the phase 1 trial of SBE303, which began last month, is scheduled to run through July 2030 and enroll 149 patients worldwide with advanced solid tumors.